Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.
| Revenue (TTM) | $6.04B |
| Gross Profit (TTM) | $2.68B |
| EBITDA | $1.64B |
| Operating Margin | 19.20% |
| Return on Equity | 11.40% |
| Return on Assets | 6.80% |
| Revenue/Share (TTM) | $61.61 |
| Book Value | $73.92 |
| Price-to-Book | 2.83 |
| Price-to-Sales (TTM) | 3.60 |
| EV/Revenue | 3.631 |
| EV/EBITDA | 13.36 |
| Quarterly Earnings Growth (YoY) | 14.00% |
| Quarterly Revenue Growth (YoY) | 7.30% |
| Shares Outstanding | $97.50M |
| Float | $97.08M |
| % Insiders | 0.30% |
| % Institutions | 100.66% |
Volatility is currently expanding
STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pressures.
PITTSBURGH, Oct. 12, 2026 /PRNewswire/ -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention. The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringing together two organizations with a shared commitment to advancing patient safety, supporting healthcare professionals, and delivering innovative solutions to the surgical environment.
The Dublin, Ireland provider of products and services to hospitals and pharmaceutical manufacturers said it expects the deal to expand its portfolio.
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026.
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
STERIS plc (STE) Q1 2027 Earnings Call Transcript
STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STE and any ticker you trade — then tracks every position and per-strategy win rate.
